Literature DB >> 1358122

Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats.

D C Hoffman1.   

Abstract

The effects of typical and atypical neuroleptics on MK-801-induced locomotor activity and stereotyped sniffing were tested. Pretreatment with the typical neuroleptic haloperidol (0.01, 0.05, 0.1, 0.5 mg/kg SC) and the dopamine D2 receptor selective antagonist eticlopride (0.005, 0.01, 0.05 mg/kg SC) each resulted in significant and dose-dependent reductions of locomotor activity and sniffing. The atypical neuroleptic clozapine (1.0, 5.0, 10.0 mg/kg SC) was somewhat unique in that all doses reduced locomotor activity, but only the highest dose (10.0 mg/kg) significantly reduced sniffing. The data support a functional interaction between glutamate and dopamine systems, and suggest that the behavioral activation associated with MK-801 may represent a valid model for detecting potential therapeutic agents in the treatment of schizophrenia. The data should be viewed as preliminary, however, until neuroleptics are characterized in other glutamate-based models that minimized or exclude the possible influence of nonspecific motor effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358122     DOI: 10.1007/bf01245347

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  35 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia.

Authors:  A Y Deutch; B Moghaddam; R B Innis; J H Krystal; G K Aghajanian; B S Bunney; D S Charney
Journal:  Schizophr Res       Date:  1991 Mar-Apr       Impact factor: 4.939

Review 2.  Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia.

Authors:  A A Grace
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

3.  NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus.

Authors:  A Imperato; M G Scrocco; S Bacchi; L Angelucci
Journal:  Eur J Pharmacol       Date:  1990-10-23       Impact factor: 4.432

Review 4.  A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine.

Authors:  S I Deutsch; J Mastropaolo; B L Schwartz; R B Rosse; J M Morihisa
Journal:  Clin Neuropharmacol       Date:  1989-02       Impact factor: 1.592

5.  In vivo demonstration of the enhancement of MK-801 by L-glutamate.

Authors:  R B Raffa; M E Ortegón; D M Robisch; G E Martin
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

6.  Animal models with construct validity for schizophrenia.

Authors:  B.A. Ellenbroek; A.R. Cools
Journal:  Behav Pharmacol       Date:  1990       Impact factor: 2.293

7.  The NMDA antagonist dizocilpine (MK-801) reverses haloperidol-induced movement initiation deficits.

Authors:  W Hauber; W J Schmidt
Journal:  Behav Brain Res       Date:  1990-12-14       Impact factor: 3.332

8.  Detection of the nueroleptic properties of clozapine, sulpiride and thioridazine.

Authors:  B Costall; R J Naylor
Journal:  Psychopharmacologia       Date:  1975-07-23

9.  Phencyclidine-induced psychosis.

Authors:  R M Allen; S J Young
Journal:  Am J Psychiatry       Date:  1978-09       Impact factor: 18.112

10.  Potential neuroleptic agents. 4. Chemistry, behavioral pharmacology, and inhibition of [3H]spiperone binding of 3,5-disubstituted N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamides.

Authors:  T de Paulis; Y Kumar; L Johansson; S Rämsby; H Hall; M Sällemark; K Angeby-Möller; S O Ogren
Journal:  J Med Chem       Date:  1986-01       Impact factor: 7.446

View more
  24 in total

1.  Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia.

Authors:  Daniel Martins-de-Souza; Maria Lebar; Christoph W Turck
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-11-19       Impact factor: 5.270

2.  Functional reactivity of the dopaminergic system following acute and chronic ketamine treatments.

Authors:  A R Owolabi; M A Akanmu; O E Ukponmwan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-12       Impact factor: 3.000

3.  Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants.

Authors:  Jason M Uslaner; Sean M Smith; Sarah L Huszar; Rashida Pachmerhiwala; Richard M Hinchliffe; Joshua D Vardigan; Pete H Hutson
Journal:  Psychopharmacology (Berl)       Date:  2009-08-26       Impact factor: 4.530

Review 4.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

5.  MK801-induced locomotor activity in preweanling and adolescent male and female rats: role of the dopamine and serotonin systems.

Authors:  Sanders A McDougall; Matthew G Apodaca; Ginny I Park; Angie Teran; Timothy J Baum; Nazaret R Montejano
Journal:  Psychopharmacology (Berl)       Date:  2020-05-22       Impact factor: 4.530

6.  The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801.

Authors:  D C Hoffman; H Donovan; J V Cassella
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats.

Authors:  A Ouagazzal; A Nieoullon; M Amalric
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine.

Authors:  V P Bakshi; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

9.  Clozapine improves dizocilpine-induced delayed alteration impairment in rats.

Authors:  W Hauber
Journal:  J Neural Transm Gen Sect       Date:  1993

10.  Social memory in mice: disruption with an NMDA antagonist and attenuation with antipsychotic drugs.

Authors:  Xue-Min Gao; Gregory I Elmer; Beverley Adams-Huet; Carol A Tamminga
Journal:  Pharmacol Biochem Behav       Date:  2008-12-10       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.